R2

GLP-1 drug choice now affects cardiovascular outcomes. Access and reimbursement rules have not caught up

Europe Opens the SMA Gene-Therapy Door Wider

Pregnancy complications demand long-term cardiovascular care

The Transplant Is Not the Finish Line

For Pompe Infants, Time Is the Comparator

Alzheimer’s Trials Still Measure Too Little, Too Late

Global cardiovascular policy shifts accelerate, but diverging strategies expose uneven progress

West Nile Is Back. Blood Safety Cannot Lag.

Bird Flu Reached NSW. Biosecurity Is On Trial.
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
